LANDMARK Trial: a Randomised Controlled Trial of Myval THV

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 988 participants.

Also called NCT04275726

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 988 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04275726
  • EudraCT 2020-000137-40
Main results
  • LANDMARK comparison of early outcomes of newer-generation Myval transcatheter heart valve series with contemporary valves (Sapien and Evolut) in real-world individuals with severe symptomatic native aortic stenosis: a randomised non-inferiority trial Lancet (London, England), 2024-06-22 DOI, PubMed 38795719 PubMed links an erratum for this paper. Erratum: PMID 38908879; Erratum: PMID 40023648
Other papers using this trial's data
  • 1-Year Outcomes of Novel Balloon-Expandable vs Contemporary Transcatheter Heart Valves in Severe Aortic Stenosis: The LANDMARK Trial Journal of the American College of Cardiology, 2026-02-03 DOI, PubMed 41384893
  • Cardiac Damage and Clinical Outcomes in Symptomatic Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement JACC. Cardiovascular interventions, 2026-11-09 DOI, PubMed 43003595
  • Comparative 30-day echocardiographic outcomes of Myval vs. Sapien and Evolut THVs: insights from LANDMARK trial European heart journal. Cardiovascular Imaging, 2026-02-09 DOI, PubMed 40875489
  • Early outcomes of the novel Myval THV series compared to SAPIEN THV series and Evolut THV series in individuals with severe aortic stenosis EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2025-01-20 DOI, PubMed 39589296, PMC11729642 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Belarus, Brazil, Croatia, Estonia, France, Germany, Greece, Hungary, Italy, Netherlands, New Zealand, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04275726. Randomized; no masking; primary purpose treatment. Start 2020-11-04 (actual); primary completion 2024-03-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
LANDMARK Trial: a Randomised Controlled Trial of Myval THV
Acronym
LANDMARK
Condition
Aortic Valve Stenosis
Intervention (Device)
Myval THV Series
Intervention (Device)
Contemporary Valves (Sapien THV Series and Evolut THV Series)
Lead sponsor
Meril Life Sciences Pvt. Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04275726
Content hash
eb4a1168416f139b9e597d7943e2b70b8b94c1c67161dc1c7c157812b6e88b40